This is in agreement with previous studies that highlighted the synergistic antitumor activity of sorafenib combinations with EGFR inhibitors in various tumors including human non–small cell lung cancer, colorectal cancer, and HCC53,68. Here, EGFR is linked to colorectal cancer.